ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.
The Company is pleased to confirm that the first US sites are open for recruitment of patients. This will be acknowledged on the U.S. National Institutes of Health – ClincialTrials.gov website shortly. Recruitment in this pivotal Phase III study for Lupuzor™ is anticipated to occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe to ensure the screening of 270 potential patients, in order to recruit the required 200 patients for the trial. This trial is due to be completed by the end of 2017. Further updates on the progression of the Lupuzor™ Phase III trial will be announced by the company, as appropriate, as the trial progresses.
ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.